• Age 18\

⁃ 75 years old, both male and female;

• Histologically or cytologically confirmed unresectable locally advanced, or recurrent/metastatic biliary tract adenocarcinoma (including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma);

• Has not received prior systemic anti-tumor therapy;

• At least one measurable lesion based on RECIST v1.1 criteria;

• ECOG PS score: 0-1 points;

• Expected survival period ≥ 3 months;

• Adequate organ function;

• Must take one medically approved contraceptive measure;

• Patients voluntarily joined the study and signed informed consent.